News >

Expert Anticipates Cure in Acute Lymphoblastic Leukemia

Jason Harris
Published: Thursday, Aug 30, 2018

In addition, we have inotuzumab ozogamicin which is an anti-CD22 plus ozogamicin. We explored this drug at The University of Texas MD Anderson Cancer Center on a single-arm trial. We have explored different schedules and reported that the weekly regimen is better, safer, and as effective. That led to a trial called INO-VATE. Patients were randomized to receive either standard of care or inotuzumab ozogamicin given on a weekly schedule. There was an 80% response rate favoring the treatment with inotuzumab ozogamicin compared with 30% for standard of care. There was a high rate of MRD negativity with a high rate of survival as well; we have a survival rate of 23% compared with 10% for standard of care. Based on these data, the drug was approved for patients with relapsed/refractory ALL.

The field is evolving. We're exploring a new generation of CAR T cells and we're moving into earlier relapses rather than later relapses.

What are the biggest challenges in treating ALL?

These drugs are very effective, but I don't think that using them in [later lines of therapy] is where the money is. We need to use these drugs upfront in the first salvage setting. We're exploring these drugs in a frontline setting because when we can improve outcomes on a larger scale, then we can…try to use them in combination with different agents. For example, with blinatumomab and inotuzumab ozogamicin, there are data showing that we can combine them together with chemotherapy and further improve outcomes. One of the challenges is that ALL is a rare disease. Community physicians should refer these patients to big institutions until they are familiar with the drugs.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication